5 Stocks Pushing The Health Services Industry Lower

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 20 points (-0.2%) at 12,795 as of Monday, Nov. 12, 2012, 11:49 AM ET. The NYSE advances/declines ratio sits at 1,283 issues advancing vs. 1,555 declining with 129 unchanged.

The Health Services industry currently sits down 0.1% versus the S&P 500, which is down 0.1%. On the negative front, top decliners within the industry include ResMed ( RMD), down 3.2%, St Jude Medical ( STJ), down 1.7% and Becton Dickinson ( BDX), down 0.8%.

TheStreet Ratings group would like to highlight 5 stocks pushing the industry lower today:

5. Edwards Life ( EW) is one of the companies pushing the Health Services industry lower today. As of noon trading, Edwards Life is down $1.53 (-1.7%) to $86.17 on light volume Thus far, 133,599 shares of Edwards Life exchanged hands as compared to its average daily volume of 1.0 million shares. The stock has ranged in price between $86.10-$87.88 after having opened the day at $87.86 as compared to the previous trading day's close of $87.70.

Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases or critically ill patients worldwide. Edwards Life has a market cap of $10.0 billion and is part of the health care sector. The company has a P/E ratio of 38.0, above the S&P 500 P/E ratio of 17.7. Shares are up 22.5% year to date as of the close of trading on Friday. Currently there are 8 analysts that rate Edwards Life a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates Edwards Life as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, growth in earnings per share, increase in net income and good cash flow from operations. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Edwards Life Ratings Report now.

4. As of noon trading, HCA Holdings ( HCA) is down $0.28 (-0.9%) to $32.34 on light volume Thus far, 785,233 shares of HCA Holdings exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $32.34-$32.99 after having opened the day at $32.53 as compared to the previous trading day's close of $32.62.

HCA Holdings, Inc., through its subsidiaries, provides health care services in the United States. HCA Holdings has a market cap of $14.2 billion and is part of the health care sector. The company has a P/E ratio of 4.8, below the S&P 500 P/E ratio of 17.7. Shares are up 48.1% year to date as of the close of trading on Friday. Currently there are 16 analysts that rate HCA Holdings a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates HCA Holdings as a sell. The company's weaknesses can be seen in multiple areas, such as its poor profit margins and feeble growth in its earnings per share. Get the full HCA Holdings Ratings Report now.

3. As of noon trading, Thermo Fisher Scientific ( TMO) is down $0.35 (-0.6%) to $60.34 on light volume Thus far, 339,530 shares of Thermo Fisher Scientific exchanged hands as compared to its average daily volume of 1.8 million shares. The stock has ranged in price between $60.12-$60.81 after having opened the day at $60.81 as compared to the previous trading day's close of $60.69.

Thermo Fisher Scientific, Inc. provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacture, analysis, discovery, and diagnostics. Thermo Fisher Scientific has a market cap of $21.5 billion and is part of the health care sector. The company has a P/E ratio of 19.1, above the S&P 500 P/E ratio of 17.7. Shares are up 32.9% year to date as of the close of trading on Friday. Currently there are 14 analysts that rate Thermo Fisher Scientific a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Thermo Fisher Scientific as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, impressive record of earnings per share growth and increase in net income. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook. Get the full Thermo Fisher Scientific Ratings Report now.

2. As of noon trading, Cigna ( CI) is down $0.41 (-0.8%) to $51.24 on average volume Thus far, 1.5 million shares of Cigna exchanged hands as compared to its average daily volume of 2.2 million shares. The stock has ranged in price between $50.94-$51.96 after having opened the day at $51.83 as compared to the previous trading day's close of $51.65.

CIGNA Corporation, a health services organization, through its subsidiaries, provides insurance and related products and services in the United States and internationally. Cigna has a market cap of $14.9 billion and is part of the health care sector. The company has a P/E ratio of 9.6, below the S&P 500 P/E ratio of 17.7. Shares are up 23.0% year to date as of the close of trading on Friday. Currently there are 12 analysts that rate Cigna a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Cigna as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, increase in net income and attractive valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Cigna Ratings Report now.

1. As of noon trading, Express Scripts ( ESRX) is down $0.45 (-0.8%) to $52.90 on average volume Thus far, 2.7 million shares of Express Scripts exchanged hands as compared to its average daily volume of 5.2 million shares. The stock has ranged in price between $52.60-$53.62 after having opened the day at $53.35 as compared to the previous trading day's close of $53.35.

Express Scripts Holding Company provides a range of pharmacy benefit management (PBM) services in North America. Express Scripts has a market cap of $44.7 billion and is part of the health care sector. The company has a P/E ratio of 31.7, above the S&P 500 P/E ratio of 17.7. Shares are up 22.6% year to date as of the close of trading on Friday. Currently there are 16 analysts that rate Express Scripts a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Express Scripts as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, increase in net income, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Express Scripts Ratings Report now.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health services industry could consider ProShares Ultra Short Health Care ( RXD).

A reminder about TheStreet Ratings group: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.
null

If you liked this article you might like

3 Large-Cap Healthcare Stocks You Must Buy Following the Market Pullback

3 Large-Cap Healthcare Stocks You Must Buy Following the Market Pullback

Cramer: 10 Points to Consider

Cramer: 10 Points to Consider

7 Investment Themes You Can't Afford to Miss for 2018

7 Investment Themes You Can't Afford to Miss for 2018

Marvell Technology, Albemarle, Dominion Energy: 'Mad Money' Lightning Round

Marvell Technology, Albemarle, Dominion Energy: 'Mad Money' Lightning Round

Consumers Are Ready to Spend: Cramer's 'Mad Money' Recap (Tuesday 1/9/18)

Consumers Are Ready to Spend: Cramer's 'Mad Money' Recap (Tuesday 1/9/18)